• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5074186)   Today's Articles (190)
For: Downs TM, Szilvasi A, O'Donnell MA. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J Urol 1997;158:2311-5. [PMID: 9366382 DOI: 10.1016/s0022-5347(01)68241-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Number Cited by Other Article(s)
1
Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol 2021;4:826-828. [PMID: 32475716 DOI: 10.1016/j.euo.2020.03.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 03/23/2020] [Accepted: 03/27/2020] [Indexed: 12/16/2022]
2
Patel SG, Cohen A, Weiner AB, Steinberg GD. Intravesical therapy for bladder cancer. Expert Opin Pharmacother 2015;16:889-901. [DOI: 10.1517/14656566.2015.1024656] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
3
Lamm D, Brausi M, O'Donnell MA, Witjes JA. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 2013;32:35.e21-30. [PMID: 23628309 DOI: 10.1016/j.urolonc.2013.02.010] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Revised: 02/05/2013] [Accepted: 02/06/2013] [Indexed: 01/01/2023]
4
Santhanam S, Decatris M, O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. BioDrugs 2003;16:349-72. [PMID: 12408739 DOI: 10.2165/00063030-200216050-00004] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
5
O’DONNELL MICHAELA, KROHN JANICE, DeWOLF WILLIAMC. SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED. J Urol 2001. [DOI: 10.1016/s0022-5347(05)65757-6] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
6
SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-??2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILED. J Urol 2001. [DOI: 10.1097/00005392-200110000-00018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
7
Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000;10:125-44. [PMID: 10936063 DOI: 10.1006/scbi.2000.0315] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
8
Brown DH, Wagner TT, Bahnson RR. Interferons and bladder cancer. Urol Clin North Am 2000;27:171-8, xi. [PMID: 10696256 DOI: 10.1016/s0094-0143(05)70245-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
9
Naitoh J, Franklin J, O'Donnell MA, Belldegrun AS. Interferon alpha for the treatment of superficial bladder cancer. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2000;462:371-86; discussion 387-92. [PMID: 10599440 DOI: 10.1007/978-1-4615-4737-2_29] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
10
Luo Y, Chen X, Downs TM, DeWolf WC, O’Donnell MA. IFN-α 2B Enhances Th1 Cytokine Responses in Bladder Cancer Patients Receiving Mycobacterium bovis Bacillus Calmette-Guérin Immunotherapy. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.4.2399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
11
SUPERFICIAL BLADDER CANCER. J Urol 1998. [DOI: 10.1097/00005392-199806000-00003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
12
Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, Nseyo UO, Ratliff TL, Williams RD. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793-801. [PMID: 9598463 DOI: 10.1016/s0022-5347(01)63160-4] [Citation(s) in RCA: 89] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA